EMA CHMP gives positive opinion on belantamab mafodotin combinations for relapsed/refractory myeloma patientsAccess, Myeloma28 May 2025
European Commission approves linvoseltamab for the treatment of relapsed and refractory myelomaAccess, Myeloma29 April 2025
EMA CHMP gives positive opinion on linvoseltamab for relapsed/refractory myeloma patientsAccess, Myeloma, News3 March 2025
Register for MPE´s European Young Myeloma Patients Group webinar on myeloma and physical fitnessMPE, Myeloma, News5 February 2025
